AB 183 revises Nevada’s optometry licensing and regulatory framework in a number of ways. It declares that an optometry license is a revocable privilege intended to protect public health and safety, and it creates a process for the Nevada State Board of Optometry to summarily suspend a license when a licensee’s practice poses an imminent or continuing risk to the public or patients. The bill also expands the Board from four to five members, with four members now required to be licensed optometrists, and tightens or clarifies several licensing and certification standards, including endorsement licensure, pharmaceutical-agent certification, glaucoma certification, and the scope of controlled-substance prescribing.
The bill also modernizes and broadens the statutory definition of optometric practice to expressly include optometric telemedicine, and it extends existing supervision rules for assistants to telemedicine settings. It authorizes the Board to issue investigative orders, including compelling a licensee to appear, and it narrows reporting obligations for out-of-state administrative fines that are not reported to the National Practitioner Data Bank and are not tied to formal discipline. In addition, it creates a temporary ownership pathway for a guardian or guardian ad litem to operate an optometry practice when a sole-owner licensee is permanently incapacitated, similar to the existing rule for surviving family members after death.
The bill’s impact on state law is substantial within Chapter 636 of the Nevada Revised Statutes. It changes Board composition and enforcement authority, adjusts the qualifications and procedures for licensure and specialty certification, and limits when citations may be used and when they count as formal discipline. It also affects optometrists, applicants for licensure by endorsement, assistants working under optometrists, guardians or family members managing a practice after incapacity or death, and the Board itself, which gains additional oversight and emergency-suspension tools.
The general sentiment reflected in the voting history appears strongly favorable and noncontroversial: the bill passed the Assembly 42-0 and the Senate 21-0. No committee transcript excerpts were provided, so there is no recorded floor or committee debate to indicate opposition in the available materials. The unanimous votes suggest broad bipartisan support for the bill’s mix of public-safety protections, telemedicine updates, and professional-regulation refinements.
The main points of potential contention, based on the bill text itself, are the expanded disciplinary and emergency powers of the Board, the removal of the 40-hour ophthalmologist-led clinical training requirement for pharmaceutical-agent certification, and the changes to controlled-substance prescribing and citation rules. Some stakeholders could view the summary-suspension authority and investigative compulsion powers as stronger regulatory enforcement, while others may see the telemedicine and licensure streamlining provisions as modernization. However, the recorded votes do not show any active opposition.
AB 183 amends multiple provisions in Chapter 636 of NRS governing optometry. It expands the Nevada State Board of Optometry, revises licensure-by-endorsement and specialty-certification requirements, clarifies that optometric telemedicine is part of the practice of optometry, and changes disciplinary, citation, and reporting rules. The bill also creates a temporary ownership mechanism for a guardian or guardian ad litem to operate a permanently incapacitated optometrist’s sole-owned practice, affecting both practitioners and the Board’s enforcement and oversight authority.
The available voting history indicates very strong support for the bill, with unanimous passage in both chambers (42-0 in the Assembly and 21-0 in the Senate). No committee transcript excerpts were provided, so there is no documented debate in the supplied materials. Overall, the bill appears to have been viewed as a broadly acceptable update to optometry regulation rather than a controversial measure.
Potential areas of contention include the bill’s expansion of the Board’s authority to summarily suspend licenses and compel appearances during investigations, which increases regulatory leverage over licensees. The bill also removes a prior 40-hour clinical training requirement for pharmaceutical-agent certification and narrows when citations may be issued and reported, changes that could draw differing views from regulators, practitioners, and patient-safety advocates. Another possible issue is the broader authorization for optometric telemedicine and the related supervision rules, though the unanimous votes suggest these concerns did not generate visible opposition in the recorded legislative action.